MRI-Guided Focal Laser Ablation for Prostate Tumors
Author Information
Author(s): Marcelin Clément, Klein Clément, Robert Grégoire, Bladou Franck, Grenier Nicolas, Jambon Eva
Primary Institution: Centre Hospitalier Universitaire de Bordeaux
Hypothesis
MRI-guided focal laser ablation (MRI-FLA) is an effective treatment for localized prostate tumors with minimal side effects.
Conclusion
MRI-FLA is safe, feasible, and effective, although further trials are required.
Supporting Evidence
- Overall residual disease prevalence after ablation was 20.37%.
- Cancer-free survival rate was 75.62%.
- Rate of major and minor adverse effects was 14.26%.
- Mean decrease in PSA levels was 39.25%.
- Procedure times varied from 122 to 292 minutes.
Takeaway
Doctors can use a special laser guided by MRI to treat prostate cancer, which helps to kill the cancer while keeping the rest of the body safe.
Methodology
A systematic review and meta-analysis of nine clinical trials evaluating MRI-FLA for prostate tumors.
Potential Biases
High risk of bias due to limitations in random sequence generation and allocation concealment.
Limitations
High risk of bias in included studies and limited long-term data.
Participant Demographics
Patients with localized prostate tumors, mean age 62-66 years.
Statistical Information
P-Value
p = 0.03
Confidence Interval
12.56–29.28%
Statistical Significance
p < 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website